Logo image of OABI

OMNIAB INC (OABI) Stock Fundamental Analysis

NASDAQ:OABI - Nasdaq - US68218J1034 - Common Stock - Currency: USD

1.77  +0.07 (+4.12%)

After market: 1.69 -0.08 (-4.52%)

Fundamental Rating

3

OABI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. While OABI has a great health rating, there are worries on its profitability. While showing a medium growth rate, OABI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

OABI had negative earnings in the past year.
In the past year OABI has reported a negative cash flow from operations.
OABI had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: OABI reported negative operating cash flow in multiple years.
OABI Yearly Net Income VS EBIT VS OCF VS FCFOABI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -19.05%, OABI is in line with its industry, outperforming 42.86% of the companies in the same industry.
OABI has a Return On Equity (-21.57%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -19.05%
ROE -21.57%
ROIC N/A
ROA(3y)-12.62%
ROA(5y)-10.53%
ROE(3y)-14.73%
ROE(5y)-12.64%
ROIC(3y)N/A
ROIC(5y)N/A
OABI Yearly ROA, ROE, ROICOABI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OABI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OABI Yearly Profit, Operating, Gross MarginsOABI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

More info and screens

7

2. Health

2.1 Basic Checks

OABI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OABI has been increased compared to 1 year ago.
OABI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OABI Yearly Shares OutstandingOABI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
OABI Yearly Total Debt VS Total AssetsOABI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

OABI has an Altman-Z score of 2.37. This is not the best score and indicates that OABI is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.37, OABI is doing good in the industry, outperforming 62.50% of the companies in the same industry.
There is no outstanding debt for OABI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.37
ROIC/WACCN/A
WACC10.2%
OABI Yearly LT Debt VS Equity VS FCFOABI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.52 indicates that OABI has no problem at all paying its short term obligations.
The Current ratio of OABI (4.52) is better than 66.07% of its industry peers.
OABI has a Quick Ratio of 4.52. This indicates that OABI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.52, OABI is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.52
Quick Ratio 4.52
OABI Yearly Current Assets VS Current LiabilitesOABI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

OABI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.21%.
Looking at the last year, OABI shows a very negative growth in Revenue. The Revenue has decreased by -22.77% in the last year.
OABI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.57% yearly.
EPS 1Y (TTM)-13.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)-22.77%
Revenue growth 3Y-8.76%
Revenue growth 5Y7.57%
Sales Q2Q%124.06%

3.2 Future

The Earnings Per Share is expected to grow by 16.02% on average over the next years. This is quite good.
The Revenue is expected to grow by 29.71% on average over the next years. This is a very strong growth
EPS Next Y-2.42%
EPS Next 2Y5.64%
EPS Next 3Y10.98%
EPS Next 5Y16.02%
Revenue Next Year-11.07%
Revenue Next 2Y11.71%
Revenue Next 3Y27.19%
Revenue Next 5Y29.71%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
OABI Yearly Revenue VS EstimatesOABI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
OABI Yearly EPS VS EstimatesOABI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.2 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OABI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OABI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OABI Price Earnings VS Forward Price EarningsOABI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OABI Per share dataOABI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.64%
EPS Next 3Y10.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OABI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OMNIAB INC

NASDAQ:OABI (5/1/2025, 7:25:17 PM)

After market: 1.69 -0.08 (-4.52%)

1.77

+0.07 (+4.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-18 2025-03-18/amc
Earnings (Next)05-08 2025-05-08/amc
Inst Owners54.68%
Inst Owner ChangeN/A
Ins Owners6.07%
Ins Owner Change6.22%
Market Cap216.17M
Analysts84.29
Price Target7.99 (351.41%)
Short Float %8.76%
Short Ratio10.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.32%
Min EPS beat(2)-14.18%
Max EPS beat(2)-4.45%
EPS beat(4)1
Avg EPS beat(4)-2.33%
Min EPS beat(4)-15.52%
Max EPS beat(4)24.84%
EPS beat(8)2
Avg EPS beat(8)-22.93%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-23.37%
Min Revenue beat(2)-51.31%
Max Revenue beat(2)4.57%
Revenue beat(4)2
Avg Revenue beat(4)-13.44%
Min Revenue beat(4)-51.31%
Max Revenue beat(4)29.49%
Revenue beat(8)2
Avg Revenue beat(8)-23.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.62%
PT rev (3m)-18.62%
EPS NQ rev (1m)1.3%
EPS NQ rev (3m)-12.16%
EPS NY rev (1m)-3.7%
EPS NY rev (3m)-46.04%
Revenue NQ rev (1m)-4.27%
Revenue NQ rev (3m)-36.5%
Revenue NY rev (1m)-50.21%
Revenue NY rev (3m)-50.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.19
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 3.3
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0.22
BVpS2.36
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.05%
ROE -21.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.62%
ROA(5y)-10.53%
ROE(3y)-14.73%
ROE(5y)-12.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.95%
Cap/Sales 7.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.52
Quick Ratio 4.52
Altman-Z 2.37
F-Score3
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)36.82%
Cap/Depr(5y)29.77%
Cap/Sales(3y)13.66%
Cap/Sales(5y)12.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y-2.42%
EPS Next 2Y5.64%
EPS Next 3Y10.98%
EPS Next 5Y16.02%
Revenue 1Y (TTM)-22.77%
Revenue growth 3Y-8.76%
Revenue growth 5Y7.57%
Sales Q2Q%124.06%
Revenue Next Year-11.07%
Revenue Next 2Y11.71%
Revenue Next 3Y27.19%
Revenue Next 5Y29.71%
EBIT growth 1Y-7.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.76%
EBIT Next 3Y6.61%
EBIT Next 5YN/A
FCF growth 1Y-6008.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1789.99%
OCF growth 3YN/A
OCF growth 5YN/A